

10/586124

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number  
WO 2005/072385 A2

(51) International Patent Classification: Not classified

(21) International Application Number:  
PCT/US2005/002609

(22) International Filing Date: 27 January 2005 (27.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/539,550 27 January 2004 (27.01.2004) US  
60/566,499 29 April 2004 (29.04.2004) US

(71) Applicant (for all designated States except US): BAYER  
PHARMACEUTICALS CORPORATION [US/US];  
400 Morgan Lane, West Haven, Connecticut 06516 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CLAIRMONT,  
Kevin [US/US]; 80 Merwin Circle, Cheshire, Connecticut  
06410 (US). LUMB, Kevin, J. [US/US]; 520 Granite  
Road, Guilford, Connecticut 06437 (US). BUCKHOLZ,  
Thomas [US/US]; 10 Morehouse Avenue, Milford, Con-  
necticut 06460 (US). SALHANICK, Arthur, I. [US/US];  
430 Bellevue Road, New Haven, Connecticut 06511 (US).

(74) Agents: GREENMAN, Jeffrey, M. et al.; Bayer Phar-  
maceuticals Corporation, 400 Morgan Lane, West Haven,  
Connecticut 06516 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,

[Continued on next page]

(54) Title: PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND  
THEIR PHARMACOLOGICAL METHODS OF USE



(57) Abstract: This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secre-  
tagogue polypeptides are shown to lower blood glucose in vivo upon glucose challenge. The polypeptides of this invention are also  
stable in formulation and have long half-lives. The peptides of the present invention provide a therapy for patients with decreased  
endogenous insulin secretion, for example, type 2 diabetics. The invention is also directed to a method of treating a metabolic disease  
in a mammal comprising administering a therapeutically effective amount of the peptides to said mammal.

WO 2005/072385 A2



CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.